Improved assay for R(-)-apomorphine with application to clinical pharmacokinetic studies in Parkinson's disease.

Wendy M. Ingram*, Melanie J. Priston, Graham J. Sewell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

A high performance liquid chromatographic assay for the quantitative determination of apomorphine in human plasma is described. Sample clean-up and concentration was optimised using solid-phase extraction on C18 cartridges, enabling rapid and sensitive determination of apomorphine and potential metabolites. The limit of apomorphine quantification, using fluorescence detection, was 0.5 ng/mL. The assay was stability-indicating, and allowed the detection of analytes in the presence of commonly co-administered anti-Parkinsonian drugs. Apomorphine was stable in frozen plasma containing 0.14% (w/v) ascorbic acid for 98 days, and through four freeze-thaw cycles. The assay has been used in clinical pharmacokinetic studies of apomorphine in patients with Parkinson's disease, and in preliminary studies of novel apomorphine delivery devices in volunteers.
Original languageEnglish
Pages (from-to)1-7
Number of pages0
JournalJ Chromatogr B Analyt Technol Biomed Life Sci
Volume831
Issue number0
DOIs
Publication statusPublished - 2 Feb 2006

Keywords

  • Apomorphine
  • Ascorbic Acid
  • Chromatography
  • High Pressure Liquid
  • Drug Stability
  • Freezing
  • Humans
  • Parkinson Disease
  • Reproducibility of Results
  • Sensitivity and Specificity

Fingerprint

Dive into the research topics of 'Improved assay for R(-)-apomorphine with application to clinical pharmacokinetic studies in Parkinson's disease.'. Together they form a unique fingerprint.

Cite this